Aurobindo unit terminates pact with Singapore firm to develop pentavalent vaccine

Aurobindo Pharma has terminated a license agreement through its subsidiary Auro Vaccines with Hilleman Laboratories for developing a pentavalent vaccine for children. The company asserted that this step would not materially affect its financial situation, as Auro Vaccines is not a crucial subsidiary. Despite this, Aurobindo Pharma shares rose 3.83% to Rs 1,092.05 on the BSE.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KnYi9IF
via IFTTT